Skip to main content
. Author manuscript; available in PMC: 2014 Oct 17.
Published in final edited form as: Oncogene. 2012 Jan 16;31(43):4609–4618. doi: 10.1038/onc.2011.606

Figure 6. NRG1 affects the tumorigenic potential of melanoma cells and their ability to grow in vivo.

Figure 6

A) qRT-PCR showing the levels of inhibition of NRG1 after transduction with the specific NRG1 shRNA sequences -3 and -5 in WM266-4 cells. B) Soft agar assay performed on WM266-4 cells expressing an shRNA control (shGFP), or the shNRG1-3 and -5. C) in vivo growth of the cells in B. D) Representative immunohistochemistry showing p27Kip1 and Notch1 levels in tumors originated from the assay in C and collected at 48 (shGFP) or 62 (shNRG1-3 and -5) days post-inoculation. The antibody against Notch1 is raised against Notch1-TM. The soft agar assay was repeated four times and the data in B is a representation of one of the experimental repeats. The in vivo growth was done twice.